We are joined by Niels Reinmuth (Asklepios Kliniken Munich-Gauting) at ESMO 2019 to discuss his presentation on PD-L1 expression in primary tumours versus metastatic samples in the phase III MYSTIC study in first-line metastatic NSCLC.
1. Could you tell us a little about the MYSTIC study and its major findings? (00:07)
2. What was the relationship between programmed death-ligand 1 (PD-L1) expression and the efficacy of durvalumab? (00:50)
3. How did the expression of PD-L1 differ between primary tumour and metastatic samples? (01:30)
4. What are the implications of these findings for clinical practice? (01:51)
Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.
Speaker disclosure: Neils Reinmuth disclosed a relevant relationship with AstraZeneca.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Lung Cancer
Misako Nagasaka, ELCS 2022: Results of the TRUST-II Study
touchONCOLOGY spoke to Prof Misako Nagasaka (University of California Irvine, Detroit, MI, USA) to discuss her presentation at the European Lung Cancer Summit 2022, providing the results of the TRUST-II study, a global phase II study for taletrectinib in ROS1 fusion positive lung cancer and other solid tumours. Questions What is taletrectinib […]
Niels Reinmuth, ELCS 2022: Characteristics of Long-term Survivors in the CASPIAN Study
The CASPIAN study evaluated the efficacy and safety of durvalumab plus tremelimumab and platinum-etoposide extensive-stage SCLC. touchONCOLOGY spoke to Niels Reinmuth (Munich, Germany) to discuss the characteristics of long-term survivors in the CASPIAN study. Clinical Trial Identification: NCT03043872 Questions What did the CASPIAN study teach us about the efficacy and safety of […]
Prasad S Adusumilli, ELCS 2022: Potential of CAR-T Therapy in Lung Cancer
There is still extensive ongoing research, however CAR-T technology for lung cancer is providing much promise but many challenges. touchONCOLOGY spoke to Dr Prasad S Adusumilli (Memorial Sloan-Kettering Cancer Center, New York, NY, USA) to discuss the potential of CAR-T therapy in lung cancer and the recent breakthroughs in this area. Questions […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!